Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by qwerty22on May 14, 2021 2:29pm
116 Views
Post# 33204664

RE:RE:RE:Symposium

RE:RE:RE:Symposium

Wel according to Paul/Dawn in their chat with Wino, Soleus bought in on the expectation of the company executing on the Ph3 Nash protocol and cancer Ph1 data. It's probably easier for them to get to that simple outlook not carrying all the baggage we carry.


scarlet1967 wrote: The difference between me and you is the fact you see success in running a business solely as success in running the trials.
I see the success in running the business as a result of success in running all parts of it, including cost control, strategic planning, marketing, sales and competent leadership among others.
 

qwerty22 wrote:

It's clinical, at a clinical conference. They are talking to the people that prescribe the drug. This is about clinical engagement and sales not what you want it to be. Let them run their business.

About ACTHIV

The American Conference for the Treatment of HIV (ACTHIV) is the premier conference in the US dedicated exclusively to the frontline care team and its members who are caring for persons living with or at risk of acquiring HIV. The conference delivers information on new developments and research findings that can be rapidly translated and directly applied to the clinical setting.

 

 

scarlet1967 wrote:

 

I think the purpose of it is to discuss both lipodystrophy and NASH. Would it be wonderful to get some KOLs together and arrange for a conference on a well followed platform to discuss their programs. They are trying to bring awareness to their science but the net effect would be much higher if it was targeting bigger audience.
https://www.linkedin.com/posts/theratechnologies-inc_symposium-acthiv-acthiv2021-activity-6798957933863538688-99CH


 




<< Previous
Bullboard Posts
Next >>